| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy
|
Guarneri, V.
|
|
|
20 |
7 |
p. 1193-1198
|
article
|
| 2 |
A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer
|
Colleoni, M.
|
|
|
20 |
7 |
p. 1178-1184
|
article
|
| 3 |
BRCA2 splice site mutations in an Italian breast/ovarian cancer family
|
Díez, O.
|
|
|
20 |
7 |
p. 1285
|
article
|
| 4 |
Comprehensive clinical follow-up of late effects in childhood cancer survivors shows the need for early and well-timed intervention
|
Han, J.W.
|
|
|
20 |
7 |
p. 1170-1177
|
article
|
| 5 |
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
|
Sternberg, C.N.
|
|
|
20 |
7 |
p. 1264-1269
|
article
|
| 6 |
Editorial Board
|
|
|
|
20 |
7 |
p. ii-iii
|
article
|
| 7 |
Effectiveness of organised versus opportunistic mammography screening
|
Bulliard, J.-L.
|
|
|
20 |
7 |
p. 1199-1202
|
article
|
| 8 |
Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
|
Hadji, P.
|
|
|
20 |
7 |
p. 1203-1209
|
article
|
| 9 |
FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
|
Markova, J.
|
|
|
20 |
7 |
p. 1270-1274
|
article
|
| 10 |
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
|
Tan, E.H.
|
|
|
20 |
7 |
p. 1249-1256
|
article
|
| 11 |
Immune thrombocytopenic purpura (ITP) and breast cancer. Does adjuvant therapy for breast cancer improve platelet counts in ITP?
|
Khasraw, M.
|
|
|
20 |
7 |
p. 1282-1283
|
article
|
| 12 |
in this issue
|
|
|
|
20 |
7 |
p. 1151
|
article
|
| 13 |
MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events
|
de Vogel, S.
|
|
|
20 |
7 |
p. 1216-1222
|
article
|
| 14 |
Palliative sedation therapy does not hasten death: results from a prospective multicenter study
|
Maltoni, M.
|
|
|
20 |
7 |
p. 1163-1169
|
article
|
| 15 |
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
|
Katsumata, N.
|
|
|
20 |
7 |
p. 1210-1215
|
article
|
| 16 |
Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma
|
Nutting, C.M.
|
|
|
20 |
7 |
p. 1275-1279
|
article
|
| 17 |
Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer
|
Burtness, B.
|
|
|
20 |
7 |
p. 1242-1248
|
article
|
| 18 |
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer
|
Kemeny, N.
|
|
|
20 |
7 |
p. 1236-1241
|
article
|
| 19 |
PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma
|
Buhmeida, A.
|
|
|
20 |
7 |
p. 1230-1235
|
article
|
| 20 |
Preoperative weekly cisplatin–epirubicin–paclitaxel with G-CSF support in triple-negative large operable breast cancer
|
Frasci, G.
|
|
|
20 |
7 |
p. 1185-1192
|
article
|
| 21 |
Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
|
Cohen, S.J.
|
|
|
20 |
7 |
p. 1223-1229
|
article
|
| 22 |
Reply to BRCA2 splice site mutations in an Italian breast/ovarian cancer family
|
Pensabene, M.
|
|
|
20 |
7 |
p. 1285-1286
|
article
|
| 23 |
Successful treatment of ifosfamide-induced hyponatremia with AVP receptor antagonist without interruption of hydration for prevention of hemorrhagic cystitis
|
Glezerman, I.G.
|
|
|
20 |
7 |
p. 1283-1285
|
article
|
| 24 |
Table of Contents
|
|
|
|
20 |
7 |
p. iv-v
|
article
|
| 25 |
Tamoxifen contraindicated in women with hereditary angioedema?
|
Rousset-Jablonski, C.
|
|
|
20 |
7 |
p. 1281-1282
|
article
|
| 26 |
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma
|
Planchard, D.
|
|
|
20 |
7 |
p. 1257-1263
|
article
|
| 27 |
The use of sedation to relieve cancer patients' suffering at the end of life: addressing critical issues
|
Cherny, N.
|
|
|
20 |
7 |
p. 1153-1155
|
article
|
| 28 |
Travel warning with capecitabine
|
Wong, M.
|
|
|
20 |
7 |
p. 1281
|
article
|
| 29 |
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
|
Barrios, C.H.
|
|
|
20 |
7 |
p. 1157-1162
|
article
|
Journal description